The catalytic performance of catalyst,which was formed in situ from RuCl3-TPPTS[TPPTS:P(m-C6H4SO3Na)3],for slelctive hydrogenation of carbon-carbon double bond in acrylonitrile to prepare propionitrile were studied ...The catalytic performance of catalyst,which was formed in situ from RuCl3-TPPTS[TPPTS:P(m-C6H4SO3Na)3],for slelctive hydrogenation of carbon-carbon double bond in acrylonitrile to prepare propionitrile were studied in biphasic system (aqueous/organic phase).Good conversion and excellent selectivity were obtained.We studied the effect of KOH/Ru(molar ratio),H2 pressure,P/Ru(molar ratio),concentration of Ruthenium,temperature and reaction time on the catalytic activity and selectvity.The results show that the catalytic system have good conversion and very high slectivity for the hydrogenation of carbon-carbon double bond of acrylonitrile at the same time,the catalyst were separated readily from the product.展开更多
他达拉非(tadalafil,1),化学名称为(6R,12aR)-6-(1,3-苯并二氧戊环-5-基)-2-甲基-2,3,6,7,12,12a-六氢吡嗪并[1',2':1,6]吡啶并[3,4-b]吲哚-1,4-二酮,是由美国礼来公司(Eli Lilly and Company)研发的一种新型磷酸二酯酶Ⅴ(P...他达拉非(tadalafil,1),化学名称为(6R,12aR)-6-(1,3-苯并二氧戊环-5-基)-2-甲基-2,3,6,7,12,12a-六氢吡嗪并[1',2':1,6]吡啶并[3,4-b]吲哚-1,4-二酮,是由美国礼来公司(Eli Lilly and Company)研发的一种新型磷酸二酯酶Ⅴ(PDE-5)抑制剂,该药作为治疗性功能障碍的药物于2003年在美国首次上市,2009年有文献报道该药物也可用于治疗肺动脉高压。展开更多
文摘The catalytic performance of catalyst,which was formed in situ from RuCl3-TPPTS[TPPTS:P(m-C6H4SO3Na)3],for slelctive hydrogenation of carbon-carbon double bond in acrylonitrile to prepare propionitrile were studied in biphasic system (aqueous/organic phase).Good conversion and excellent selectivity were obtained.We studied the effect of KOH/Ru(molar ratio),H2 pressure,P/Ru(molar ratio),concentration of Ruthenium,temperature and reaction time on the catalytic activity and selectvity.The results show that the catalytic system have good conversion and very high slectivity for the hydrogenation of carbon-carbon double bond of acrylonitrile at the same time,the catalyst were separated readily from the product.
文摘他达拉非(tadalafil,1),化学名称为(6R,12aR)-6-(1,3-苯并二氧戊环-5-基)-2-甲基-2,3,6,7,12,12a-六氢吡嗪并[1',2':1,6]吡啶并[3,4-b]吲哚-1,4-二酮,是由美国礼来公司(Eli Lilly and Company)研发的一种新型磷酸二酯酶Ⅴ(PDE-5)抑制剂,该药作为治疗性功能障碍的药物于2003年在美国首次上市,2009年有文献报道该药物也可用于治疗肺动脉高压。